AbbVie Initiates Two Phase 1 Trials Expanding Oncology Pipeline with ABBV-901 and ABBV-243
核心洞察
AbbVie (搜索) launched a Phase 1 trial testing ABBV-901 (搜索) in 207 adults with ovarian cancer, evaluating the experimental intravenous drug both as monotherapy and in combination with bevacizumab.
The company simultaneously initiated a Phase 1 safety study of ABBV-243 (搜索) in healthy volunteers, using a randomized, double-blind, placebo-controlled design to assess pharmacokinetics and safety.
Both trials represent AbbVie (搜索)'s strategic investment in expanding its oncology pipeline beyond current mature franchises to offset future patent cliff concerns.
AbbVie (搜索) has launched two Phase 1 clinical trials as part of its expanding oncology pipeline, marking the company's first-in-human testing of experimental compounds ABBV-901 (搜索) and ABBV-243 (搜索). The trials represent strategic investments in new oncology assets designed to diversify long-term revenue streams and address future patent cliff concerns.
ABBV-901 Ovarian Cancer Trial
The company initiated a Phase 1 trial titled "A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 (搜索) as a Monotherapy and in Combination With Bevacizumab in Adult Subjects With Ovarian Cancer." The study aims to test ABBV-901, an experimental intravenous cancer drug designed to attack ovarian cancer cells more directly.
The interventional study will enroll approximately 207 adults with ovarian cancer who will be randomly assigned to different groups receiving ABBV-901 (搜索) at rising doses, either alone or in combination with bevacizumab. The trial follows an open-label design where both doctors and patients know which treatment they are receiving. ABBV-901 will be tested alongside bevacizumab, a well-known standard treatment for ovarian cancer that helps cut off the tumor's blood supply.
The trial started enrolling after initial submission on December 2, 2025, with primary completion expected within a roughly three-year study window. The most recent update to the record on January 6, 2026, confirms the study is active and recruiting, signaling steady operational progress.
ABBV-243 Safety Study
Simultaneously, AbbVie (搜索) launched a Phase 1 trial called "A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses (SAD) of ABBV-243 (搜索) in Healthy Adult Subjects and a Single Dose in Healthy Asian Adult Subjects."
The trial tests ABBV-243 (搜索), an experimental drug administered as either an intravenous infusion or subcutaneous injection, compared with placebo in healthy volunteers. The study follows a sequential design with dose levels increased in steps as safety data become available. The double-blind design ensures neither participants nor study staff know who receives ABBV-243 or placebo.
The study was first submitted on December 15, 2025, with the most recent update on January 8, 2026, showing the program remains active and under ongoing review.
Strategic Pipeline Development
For AbbVie (搜索), these early-stage programs support the company's narrative of investing in new oncology assets to diversify long-term revenue. Positive safety and early efficacy signals from the ABBV-901 (搜索) trial could strengthen confidence in AbbVie's cancer pipeline and help offset concerns about future patent cliffs in other franchises.
In the ovarian cancer space, ABBV-901 (搜索) will compete against established players including Roche (bevacizumab), AstraZeneca, and others focused on targeted and combination therapies. Any indication that ABBV-901 pairs well with established drugs such as bevacizumab could support AbbVie (搜索)'s positioning in solid tumors and may eventually drive partnership or combination strategies across the sector.
While both trials represent early-stage development with high clinical risk and limited near-term revenue impact, they demonstrate AbbVie (搜索)'s continued investment in pipeline expansion. The steady flow of Phase 1 trial initiations keeps AbbVie competitive with peers like Pfizer and Merck in the race to feed future product pipelines.